OptiBiotix recently announced a trading update for the 12-months to Dec-21 and its intention to list its ProBiotix Health division. The company expects revenues of £2.2m, in-line with our forecast, while operational investment suggests a group level EBITDA loss of c£0.9m, driven by one off recruitment and consultancy costs, versus our previous £0.3m loss forecast. Both divisions saw revenue and EBITDA (pre-central costs) growth during the year, building on the 2020 progress. Supporting future gr ....
